• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Corvus Pharmaceuticals (CRVS)

Common Shares
Sell: $3.56|Buy: $3.70|Change: 0.07 (-1.95%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).

Address

863 Mitten Road
Suite 102
Burlingame
CA
USA
94010

Telephone

+1 650 9004522

Website

https://www.corvuspharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Corvus Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262026-05-08T16:30:00
Corvus Pharmaceuticals Inc First Quarter Earnings Results for 20262026-05-08T00:00:00
Corvus Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20252026-03-25T16:30:00
Corvus Pharmaceuticals Inc Fourth Quarter Earnings Results for 20252026-03-25T00:00:00
Corvus Pharmaceuticals Inc Annual Report for 20252026-03-25T00:00:00
Corvus Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20252025-11-12T16:30:00
Corvus Pharmaceuticals Inc Third Quarter Earnings Results for 20252025-11-12T00:00:00
Corvus Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20252025-08-06T16:30:00
Corvus Pharmaceuticals Inc Second Quarter Earnings Results for 20252025-08-06T00:00:00
Corvus Pharmaceuticals Inc Annual General Meeting for 20242025-06-13T13:00:00
Corvus Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-08T16:30:00
Corvus Pharmaceuticals Inc First Quarter Earnings Result for 20252025-05-08T00:00:00

Previous key dates

NameKey Date
Corvus Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-08T16:30:00
Corvus Pharmaceuticals Inc First Quarter Earnings Result for 20252025-05-08T00:00:00
H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, 20252025-03-27T12:00:00
Corvus Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20242025-03-25T16:30:00
Corvus Pharmaceuticals Inc Fourth Quarter Earnings Result for 20242025-03-25T00:00:00
Corvus Pharmaceuticals Inc Annual Report for 20242025-03-25T00:00:00
Oppenheimer 35th Annual Healthcare Life Sciences Conference2025-02-11T09:20:00
43rd Annual J.P. Morgan Healthcare Conference2025-01-15T14:15:00
Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis2024-12-18T08:00:00
Corvus Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20242024-11-12T16:30:00
Corvus Pharmaceuticals Inc Third Quarter Earnings Results for 20242024-11-12T00:00:00
H.C. Wainwright 26th Annual Global Investment Conference2024-09-10T12:00:00
Corvus Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20242024-08-06T16:30:00
Corvus Pharmaceuticals Inc Second Quarter Earnings Result for 20242024-08-06T00:00:00
Corvus Pharmaceuticals Inc Annual General Meeting for 20232024-06-13T13:00:00
Jefferies Global Health Conference2024-06-05T15:00:00
Corvus Pharmaceuticals Inc First Quarter Earnings Conference Call for 20242024-05-06T16:30:00
Corvus Pharmaceuticals Inc First Quarter Earnings Result for 20242024-05-06T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.